Precision Medicine in Oncology®

Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on How the Institutes in the mutlicenter study examining driver mutations Worked Together

Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.

Dr. Jack West from Swedish Cancer Institute Discusses 4 Important Upcoming Clinical Trials Results in Lung Cancer.

Dr. Apostolia Tsimberidou from MD Anderson Cancer Center on the Next Steps for Personalized Care

Intense research has resulted in JAK-STAT becoming one of the best-understood signal transduction cascades.

Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses the Field of Mutation Testing

Dr. Axel Hoos medical lead at Bristol-Myers Squibb on Why Melanoma is Amenable to Immunotherapy

Findings from a randomized phase III trial in China suggest erlotinib is suitable for first-line treatment in patients with EGFR mutation-positive NSCLC.

Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.

Dr. Mark G. Kris from Memorial Sloan-Kettering cancer center Explains How Gene Signatures are Used

Dr. Brian I. Rini from the Taussig Cancer Institute Describes Hypertension as a Biomarker in RCC

Dr. Jack West from Swedish Cancer Institute Explains the Pemetrexed Clinical Trial

Dr. Apostolia M. Tsimberidou from MD Anderson Cancer Center on the Personalized Medicine Study Results

Karen Hagemaster from Advocate Good Samaritan Hospital on Chemotherapy Documentation Study

Dr. Mark G. Kris thoracic chair at Memorial Sloan-Kettering Cancer Center Discusses Driver Mutations Test False Negatives

Dr. Jack West Swedish Cancer Institute on the Gefitinib Advanced non-small cell lung cancer Trial

Dr. Axel Hoos from Bristol-Myers Squibb Explains the Future of Immunotherapy and Ipilimumab's role

Researchers are continuing to explore whether ixabepilone (Ixempra) is a better choice as adjuvant chemotherapy for patients with early-stage, triple-negative breast cancer than the standard paclitaxel (Taxol).

Dr. Tim J. Whelan from Juravinski Cancer Centre Provides a MA.20 Trial Result Summary

Even before the FDA approved ipilimumab in March, the field of cancer immunotherapy was a lively area of scientific inquiry.

Dr. Axel Hoos medical lead from Bristol-Myers Squibb Describes Ipilimumab and Future Immunotherapies

Dr. Tim Turnham the executive director of the melanoma research foundation Describes the organization

Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success